Galera Therapeutics Stock (NASDAQ:GRTX), Analyst Ratings, Price Targets, Predictions

The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by Citigroup on August 29, 2023. The analyst firm set a price target for $0.25 expecting GRTX to rise to within 12 months (a possible 41.24% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by Citigroup, and Galera Therapeutics maintained their neutral rating.

The last upgrade for Galera Therapeutics Inc happened on February 16, 2023 when B of A Securities raised their price target to $7. B of A Securities previously had an underperform for Galera Therapeutics Inc.

The last downgrade for Galera Therapeutics Inc happened on August 16, 2023 when HC Wainwright & Co. changed their price target from $6 to $0.3 for Galera Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.

While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a maintained with a price target of $0.40 to $0.25. The current price Galera Therapeutics (GRTX) is trading at is $0.18, which is out of the analyst’s predicted range.